Bio Path Holdings Stock Buy Hold or Sell Recommendation
| BPTH Stock | USD 0.82 0.02 2.50% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Bio Path Holdings is 'Cautious Hold'. The recommendation algorithm takes into account all of Bio Path's available fundamental, technical, and predictive indicators you will find on this site.
Check out Bio Path Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Bio and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Bio |
Execute Bio Path Buy or Sell Advice
The Bio recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Bio Path Holdings. Macroaxis does not own or have any residual interests in Bio Path Holdings or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Bio Path's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Bio Path Trading Alerts and Improvement Suggestions
| Bio Path Holdings generated a negative expected return over the last 90 days | |
| Bio Path Holdings has high historical volatility and very poor performance | |
| Bio Path Holdings has some characteristics of a very speculative penny stock | |
| Bio Path Holdings has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (16.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: Bio-Path Holdings Inc Q3 2024 Earnings Call Highlights Strategic Advances and Financial ... |
Bio Path Returns Distribution Density
The distribution of Bio Path's historical returns is an attempt to chart the uncertainty of Bio Path's future price movements. The chart of the probability distribution of Bio Path daily returns describes the distribution of returns around its average expected value. We use Bio Path Holdings price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Bio Path returns is essential to provide solid investment advice for Bio Path.
| Mean Return | -0.73 | Value At Risk | -10 | Potential Upside | 6.67 | Standard Deviation | 7.01 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Bio Path historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Bio Stock Institutional Investors
| Shares | Global Retirement Partners, Llc. | 2024-09-30 | 4.0 | Hanson Mcclain Inc | 2024-09-30 | 1.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 97 K | Hrt Financial Llc | 2024-06-30 | 14.1 K | Vanguard Group Inc | 2024-09-30 | 13.5 K | Geode Capital Management, Llc | 2024-06-30 | 10.9 K | Tower Research Capital Llc | 2024-06-30 | 3.7 K | Blackrock Inc | 2024-06-30 | 2.4 K | Ubs Group Ag | 2024-06-30 | 859 | Qube Research & Technologies | 2024-06-30 | 100.0 |
Bio Path Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 19.4M | (6.7M) | 10.0M | (13.4M) | (9.3M) | (8.9M) | |
| Free Cash Flow | (8.4M) | (11.0M) | (10.0M) | (15.1M) | (11.5M) | (11.0M) | |
| Depreciation | 230K | 151K | 161K | 178K | 204.7K | 179.9K | |
| Other Non Cash Items | 1.3M | 963K | 1.3M | 507K | 271K | 356.8K | |
| Net Income | (8.6M) | (10.9M) | (10.4M) | (13.9M) | (16.1M) | (15.3M) | |
| End Period Cash Flow | 20.4M | 13.8M | 23.8M | 10.4M | 1.1M | 999.4K | |
| Change To Netincome | 1.2M | 684K | 577K | 821K | 944.2K | 991.4K |
Bio Path Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Bio Path or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Bio Path's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Bio stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.73 | |
β | Beta against Dow Jones | -0.02 | |
σ | Overall volatility | 6.85 | |
Ir | Information ratio | -0.12 |
Bio Path Volatility Alert
Bio Path Holdings is displaying above-average volatility over the selected time horizon. Bio Path Holdings is a potential penny stock. Although Bio Path may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Bio Path Holdings. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Bio instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Bio Path Fundamentals Vs Peers
Comparing Bio Path's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Bio Path's direct or indirect competition across all of the common fundamentals between Bio Path and the related equities. This way, we can detect undervalued stocks with similar characteristics as Bio Path or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Bio Path's fundamental indicators could also be used in its relative valuation, which is a method of valuing Bio Path by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Bio Path to competition |
| Fundamentals | Bio Path | Peer Average |
| Return On Equity | -3.66 | -0.31 |
| Return On Asset | -1.4 | -0.14 |
| Current Valuation | 2.86 M | 16.62 B |
| Shares Outstanding | 4.31 M | 571.82 M |
| Shares Owned By Institutions | 1.08 % | 39.21 % |
| Number Of Shares Shorted | 77.76 K | 4.71 M |
| Price To Earning | (6.21) X | 28.72 X |
| Price To Book | 2.33 X | 9.51 X |
| EBITDA | (15.76 M) | 3.9 B |
| Net Income | (16.08 M) | 570.98 M |
| Cash And Equivalents | 17.02 M | 2.7 B |
| Cash Per Share | 2.38 X | 5.01 X |
| Total Debt | 113 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 15.57 X | 2.16 X |
| Book Value Per Share | 0.71 X | 1.93 K |
| Cash Flow From Operations | (11.54 M) | 971.22 M |
| Short Ratio | 0.03 X | 4.00 X |
| Earnings Per Share | (8.34) X | 3.12 X |
| Target Price | 12.0 | |
| Number Of Employees | 10 | 18.84 K |
| Beta | 0.22 | -0.15 |
| Market Capitalization | 3.44 M | 19.03 B |
| Total Asset | 3.22 M | 29.47 B |
| Retained Earnings | (107.61 M) | 9.33 B |
| Working Capital | 1.14 M | 1.48 B |
| Current Asset | 9.59 M | 9.34 B |
| Current Liabilities | 937 K | 7.9 B |
| Net Asset | 3.22 M |
Note: Acquisition by Garrison Thomas E of 400000 shares of Bio Path at 1.5 subject to Rule 16b-3 [view details]
Bio Path Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Bio . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 4711.59 | |||
| Daily Balance Of Power | 0.1667 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 0.81 | |||
| Day Typical Price | 0.81 | |||
| Price Action Indicator | 0.02 | |||
| Period Momentum Indicator | 0.02 |
About Bio Path Buy or Sell Advice
When is the right time to buy or sell Bio Path Holdings? Buying financial instruments such as Bio Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Bio Path in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Blockchain Thematic Idea Now
Blockchain
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Bio Path Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.